Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | replication factor A 73 kDa subunit | 0.0316 | 1 | 1 |
Echinococcus multilocularis | replication protein A 70 kDa DNA binding | 0.0316 | 1 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.1127 | 0.0507 |
Leishmania major | replication factor A, 51kDa subunit, putative | 0.0151 | 0.3901 | 0.5 |
Trypanosoma brucei | Replication factor A protein 1 | 0.0151 | 0.3901 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.1127 | 0.0507 |
Trichomonas vaginalis | replication factor A 1, rfa1, putative | 0.03 | 0.9422 | 0.9053 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.1127 | 0.0507 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.1127 | 0.0507 |
Schistosoma mansoni | replication factor A 1 rfa1 | 0.0316 | 1 | 1 |
Plasmodium falciparum | replication protein A1, large subunit | 0.0151 | 0.3901 | 0.5 |
Toxoplasma gondii | replication factor-a protein 1 (rpa1) subfamily protein | 0.0151 | 0.3901 | 1 |
Echinococcus granulosus | replication protein A 70 kDa DNA binding | 0.0316 | 1 | 1 |
Entamoeba histolytica | replication factor A protein 1, putative | 0.0136 | 0.3324 | 0.5 |
Brugia malayi | RNA binding protein | 0.0076 | 0.1127 | 0.0507 |
Onchocerca volvulus | Putative replication factor A 73 kDa subunit | 0.0282 | 0.877 | 0.5 |
Plasmodium vivax | replication protein A1, large subunit, putative | 0.0151 | 0.3901 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.1127 | 0.0507 |
Trichomonas vaginalis | replication factor A 1, rfa1, putative | 0.0316 | 1 | 1 |
Trichomonas vaginalis | replication factor A 1, rfa1, putative | 0.0316 | 1 | 1 |
Trypanosoma cruzi | Replication factor A protein 1 | 0.0151 | 0.3901 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0046 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.6626 uM | PubChem BioAssay. qHTS of Nrf2 Activators: Hit Validation in Primary Assay. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 3.9811 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 6.3096 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of Nrf2 Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 13.1154 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | ||
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.